Boston Scientific Acquires Valencia Technologies to Advance UUI Solutions

Boston Scientific has acquired Valencia Technologies for an undisclosed amount, marking a strategic expansion in its urology and pelvic health portfolio.

Valencia Technologies is dedicated to transforming the management of urge urinary incontinence (UUI) through its innovative solutions.

This acquisition signifies Boston Scientific's commitment to providing comprehensive treatment options for patients suffering from UUI.

Valencia Technologies offers a distinct approach to UUI treatment with its eCOIN implant, providing patients with over three years of "set it and forget it" relief.

Unlike many traditional options, this technology aims to free patients from concerns over daily medications, frequent doctor visits, repetitive procedures, or the need for surgery and general anesthesia.

A peer-reviewed study highlighted the patient preference for eCOIN, showing that almost one in five UUI patients chose it as their first option among advanced treatments.

The technology also benefits healthcare providers by increasing practice efficiency, reducing office visits for established patients, and creating opportunities for new patient intake and additional revenue.

Surgery centers and hospitals can also enhance their economics as the eCoin implant can be performed in a procedure room without general anesthesia.

This acquisition is strategically important for Boston Scientific, a global medical technology leader.

Valencia's eCOIN technology complements Boston Scientific's existing offerings in urology, allowing the company to address a broader spectrum of patient needs with a less invasive, long-term solution.

The integration of Valencia's innovative UUI management system into Boston Scientific's extensive commercial infrastructure is expected to accelerate the adoption of eCOIN globally, leveraging Boston Scientific's market reach and expertise to bring this technology to more patients and providers.

The combined entity is poised to deliver enhanced solutions for urge urinary incontinence, aiming to improve patient quality of life and streamline clinical workflows.

This move is anticipated to strengthen Boston Scientific's position in the urology market by offering a differentiated and highly valued treatment option.